Log in

Cara Therapeutics Stock Price, News & Analysis (NASDAQ:CARA)

$18.84
+0.22 (+1.18 %)
(As of 10/14/2019 06:55 AM ET)
Today's Range
$18.47
Now: $18.85
$18.95
50-Day Range
$17.76
MA: $21.60
$24.25
52-Week Range
$12.19
Now: $18.85
$27.55
Volume407,733 shs
Average Volume830,178 shs
Market Capitalization$754.37 million
P/E RatioN/A
Dividend YieldN/A
Beta2.22
Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CARA
CUSIPN/A
Phone203-406-3700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.47 million
Book Value$3.38 per share

Profitability

Net Income$-74,010,000.00
Net Margins-420.97%

Miscellaneous

Employees55
Market Cap$754.37 million
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive CARA News and Ratings via Email

Sign-up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter.


Cara Therapeutics (NASDAQ:CARA) Frequently Asked Questions

What is Cara Therapeutics' stock symbol?

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics Inc (NASDAQ:CARA) announced its earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($0.58) EPS for the quarter, beating analysts' consensus estimates of ($0.61) by $0.03. The biopharmaceutical company had revenue of $5.21 million for the quarter, compared to analysts' expectations of $5.14 million. Cara Therapeutics had a negative return on equity of 68.36% and a negative net margin of 420.97%. View Cara Therapeutics' Earnings History.

When is Cara Therapeutics' next earnings date?

Cara Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Cara Therapeutics.

What price target have analysts set for CARA?

9 analysts have issued 12 month price objectives for Cara Therapeutics' shares. Their predictions range from $13.36 to $39.00. On average, they anticipate Cara Therapeutics' stock price to reach $26.93 in the next twelve months. This suggests a possible upside of 42.9% from the stock's current price. View Analyst Price Targets for Cara Therapeutics.

What is the consensus analysts' recommendation for Cara Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cara Therapeutics.

What are Wall Street analysts saying about Cara Therapeutics stock?

Here are some recent quotes from research analysts about Cara Therapeutics stock:
  • 1. According to Zacks Investment Research, "Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. " (10/8/2019)
  • 2. HC Wainwright analysts commented, "Our $28 price target (from $26) is based on an overall 80% probability of success adjusted-DCF analysis including just Korsuva U.S. sales in CKD-aP, comprising peak IV Korsuva annual sales over $500M in the hemodialysis population, and further risk-discount oral Korsuva sales in Stage 3-5 CKD. The latter oral component’s $100M peak sales in our model reflects still a conservative 40% probability of success ($300M de-risked). Our DCF reflects a 10% WACC discount and 0% terminal growth beyond 2028." (5/29/2019)

Has Cara Therapeutics been receiving favorable news coverage?

News coverage about CARA stock has been trending negative on Monday, according to InfoTrie. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Cara Therapeutics earned a media sentiment score of -2.6 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Cara Therapeutics.

Are investors shorting Cara Therapeutics?

Cara Therapeutics saw a decline in short interest in September. As of September 30th, there was short interest totalling 5,670,000 shares, a decline of 5.3% from the August 30th total of 5,990,000 shares. Based on an average trading volume of 837,800 shares, the days-to-cover ratio is currently 6.8 days. Approximately 13.4% of the company's stock are sold short. View Cara Therapeutics' Current Options Chain.

Who are some of Cara Therapeutics' key competitors?

What other stocks do shareholders of Cara Therapeutics own?

Who are Cara Therapeutics' key executives?

Cara Therapeutics' management team includes the folowing people:
  • Dr. Derek T. Chalmers, Co-Founder, Pres, CEO & Director (Age 55)
  • Dr. Frédérique Menzaghi, Chief Scientific Officer and Sr. VP of R&D (Age 53)
  • Dr. Joana Goncalves, Chief Medical Officer (Age 45)
  • Dr. Joseph Stauffer, Consultant (Age 53)
  • Dr. Michael E. Lewis, Co-Founder & Chief Scientific Advisor (Age 67)

Who are Cara Therapeutics' major shareholders?

Cara Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Rothschild Investment Corp IL (0.07%). Company insiders that own Cara Therapeutics stock include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joseph William Stauffer, Mani Mohindru and Scott Terrillion. View Institutional Ownership Trends for Cara Therapeutics.

Which major investors are selling Cara Therapeutics stock?

CARA stock was sold by a variety of institutional investors in the last quarter, including Rothschild Investment Corp IL. Company insiders that have sold Cara Therapeutics company stock in the last year include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joseph William Stauffer, Mani Mohindru and Scott Terrillion. View Insider Buying and Selling for Cara Therapeutics.

How do I buy shares of Cara Therapeutics?

Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cara Therapeutics' stock price today?

One share of CARA stock can currently be purchased for approximately $18.85.

How big of a company is Cara Therapeutics?

Cara Therapeutics has a market capitalization of $754.37 million and generates $13.47 million in revenue each year. The biopharmaceutical company earns $-74,010,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Cara Therapeutics employs 55 workers across the globe.View Additional Information About Cara Therapeutics.

What is Cara Therapeutics' official website?

The official website for Cara Therapeutics is http://www.caratherapeutics.com/.

How can I contact Cara Therapeutics?

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at 203-406-3700.


MarketBeat Community Rating for Cara Therapeutics (NASDAQ CARA)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  570 (Vote Outperform)
Underperform Votes:  310 (Vote Underperform)
Total Votes:  880
MarketBeat's community ratings are surveys of what our community members think about Cara Therapeutics and other stocks. Vote "Outperform" if you believe CARA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CARA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Featured Article: Gap Up Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel